Resverlogix

Provider of small molecule BET-inhibitors for CV disease for treating diabetes

placeCalgary, Alberta, Canada calendar_todayFounded 2001 groups19 employees language resverlogix.com

Innovation

28 patent families (14 granted) — focus: Human necessities, Chemistry & metallurgy, Physics & computing; filing pace slowing. Cited 13,029 times.

YearFilings
201510
201610
201711
20187
20195
20206
20217
20228
20235
20245
20256
20261

Social engagement

Social engagement: 1.9K social following, 1 post in the last 12 months — below the industry typical range.

Investor mix

5 investors on record.

Investor typeCountShare
Venture capital120%
Private equity240%
Other / undisclosed240%

Recent activity

18 Nov 2025
Leadership hire
Board of Directors
Coming soon